Skip to content
DataLookout
Menu

NCT06379217

NEPC Study: An Exploratory Safety and Efficacy Study With PSMA, SSTR2 and GRPR Targeted Radioligand Therapy in Metastatic Neuroendocrine Prostate Cancer.

StatusTerminated
PhasePhase 1
Primary completion
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 33 versions: 27 with changes below, 6 re-verified with no change. See every version on ClinicalTrials.gov ↗

  1. Stopped Trial terminated Sponsor's reason: Sponsor decision and not a consequence of any safety concerns.
    • Primary completion date changed from estimate of Sep 11, 2026 to Oct 16, 2026
    • Secondary endpoints: 18 to 16
    • Study description shortened, about 1 word
  2. Minor Primary and study completion dates: Sep 11, 2026 to Oct 9, 2026
  3. Notable Eligibility criteria expanded, about 17 words Show 5 more changesShow less
    • Primary endpoints: details revised at 1 of 2 entries
    • Primary and study completion dates: Aug 31, 2026 to Sep 11, 2026
    • Interventions: Antiemetics & antinauseants (Drug), GnRH antagonists (Drug), Gonadotropin-releasing hormone (GnRH) analogues (Drug), L-Lysine… to Antiemetics & antinauseants (Drug), GnRH antagonists (Drug), Gonadotropin-releasing hormone (GnRH) analogues (Drug), L-Lysine…
    • Secondary endpoints: details revised at 13 of 18 entries
    • Study description revised
  4. Minor Primary and study completion dates: Aug 24, 2026 to Aug 31, 2026v29
  5. Minor Study sites: 11 to 9v26
Show 21 earlier versionsHide 21 earlier versions
  1. Minor Primary and study completion dates: Aug 27, 2026 to Aug 24, 2026
    • Study description expanded, about 11 words
    v25
  2. Minor Enrollment target: 28 to 31
    • Primary and study completion dates: Jun 23, 2027 to Aug 27, 2026
    v24
  3. Minor Trial status: Recruiting to Active, Not Recruiting
    • Enrollment target: estimated 36 to confirmed 28
    • Study sites: 14 to 11
    v23
  4. Minor Site details revised at 8 of 14 sitesv22
  5. Notable Eligibility criteria expanded, about 3 words
    • Study sites: 12 to 14
    • Primary and study completion dates: Jun 22, 2027 to Jun 23, 2027
    • Study description expanded, about 35 words
    v21
  6. Minor Site contacts updated at 2 of 12 sitesv20
  7. Minor Study sites: 11 to 12v19
  8. Minor Study sites: 9 to 11v18
  9. Minor Study sites: 8 to 9v17
  10. Minor Site contacts updated at 1 of 8 sitesv16
  11. Minor Site contacts updated at 1 of 8 sitesv15
  12. Minor Site contacts updated at 1 of 8 sitesv14
  13. Minor Study sites: 7 to 8v13
  14. Minor Study sites: 4 to 7v12
  15. Minor Site contacts updated at 1 of 4 sitesv11
  16. Minor Study sites: 3 to 4
    • Secondary endpoints: details revised at 1 of 18 entries
    v9
  17. Notable Primary endpoints revised (2)v7
  18. Notable Trial status: Not Yet Recruiting to Recruiting
    • Study sites: 0 to 3
    • Start date changed from estimate of Aug 31, 2024 to Jul 29, 2024
    v6
  19. Notable Start date: Jul 31, 2024 to Aug 31, 2024v5
  20. Notable Start date: Jun 18, 2024 to Jul 31, 2024v4
  21. Minor Primary and study completion dates: Jun 4, 2027 to Jun 22, 2027v3
  1. Study First Submitted
  • Stopped: terminated, suspended or withdrawn
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

Number/extent of lesions with at least a moderate uptake of any of the Radioligand Imaging (RLI)
Timeframe: Baseline (baseline imaging is performed during the 42 day screening period)
Percentage changes in quantitative PET parameters.
Timeframe: Post-Baseline (from date of baseline imaging scans to post-baseline scans, at least 6 weeks after receiving the first cycle of radioligand treatment)

Secondary (16)

Overall Response Rate (ORR)
Disease Control Rate (DCR)
Duration of response (DOR)
Radiographic Progression-free Survival (rPFS)
Proportion of participants with a decline in PSA level
Show 11 moreShow less
Incidence and severity of Adverse Events (AEs) and Serious Adverse Events (SAEs) for Radioligand Therapy (RLT)
Dose modifications for [177Lu]Lu-PSMA-617, [177Lu]Lu-DOTA-TATE and [177Lu]Lu-NeoB
Dose intensity for [177Lu]Lu-PSMA-617, [177Lu]Lu-DOTA-TATE and [177Lu]Lu-NeoB
Duration of exposure for [177Lu]Lu-PSMA-617, [177Lu]Lu-DOTA-TATE and [177Lu]Lu-NeoB
Incidence and severity of Adverse Events (AEs) and Serious Adverse Events (SAEs) for Radioligand Imaging (RLI)
Blood radioactivity concentration of [177Lu]Lu-PSMA-617, [177Lu]Lu-DOTA-TATE, [177Lu]Lu-NeoB)
Observed maximum blood concentrations (Cmax) of [177Lu]Lu-PSMA-617, [177Lu]Lu-DOTA-TATE and [177Lu]Lu-NeoB
Time of maximum blood concentration (Tmax) occurence of [177Lu]Lu-PSMA-617, [177Lu]Lu-DOTA-TATE and [177Lu]Lu-NeoB
Area under the blood concentration time curve (AUC) of [177Lu]Lu-PSMA-617, [177Lu]Lu-DOTA-TATE and [177Lu]Lu-NeoB
Absorbed radiation doses of [177Lu]Lu-PSMA-617, [177Lu]Lu-DOTA-TATE and [177Lu]Lu-NeoB
Time Activity Curves (TACs) of [177Lu]Lu-PSMA-617, [177Lu]Lu-DOTA-TATE and [177Lu]Lu-NeoB

Arms and interventions

PSMA-predominant Neuroendocrine prostate cancer (NEPC)Experimental
Somatostatin Receptor 2 (SSTR2)-predominant NEPCExperimental
Gastrin Releasing Peptide Receptor (GRPR)-predominant NEPCExperimental

Drugs: [68Ga]Ga-PSMA-11, [68Ga]GA-DOTA-TATE, [68Ga]Ga-NeoB, [177Lu]Lu-PSMA-617, [177Lu]Lu-DOTA-TATE, [177Lu]Lu-NeoB, L-Lysine HCl-L-Arginine HCl, 2.5 %,, Gonadotropin-releasing hormone (GnRH) analogues, GnRH antagonists, Antiemetics & antinauseants, Metoclopramide

Sites

9 sites in 5 countries

Germany 2, Spain 2, United Kingdom 2, United States 2, France 1